Home > Insider Trading > Filing (0000950103-20-020496)

Filing Details

Accession Number:: 0000950103-20-020496
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-10-22 21:48:11
Reporting Period:: 2020-10-20

Accepted Time:: 2020-10-22 21:48:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1802768	Royalty Pharma Plc	RPRX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1016835	B Rory Riggs	C/O Royalty Pharma Plc 110 E. 59Th Street New York NY 10022		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Ordinary Shares	Acquisiton	2020-10-20	463,200	$0.00	463,200	No	4	C	Direct
Class A Ordinary Shares	Disposition	2020-10-20	463,200	$42.00	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Ordinary Shares	LP interests in RPI US Partners 2019, LP	Disposition	2020-10-20	46,320	$0.00	463,200	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
191,681			No	4	C	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Class A Ordinary Shares	15,000	Indirect	By Spouse

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Class A Ordinary Shares	LP interests in RPI US Partners 2019, LP	$0.00			4,352,670	435,267	Direct
Class A Ordinary Shares	LP interests in RPI US Partners 2019, LP	$0.00			2,538,890	253,889	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
	4,352,670	435,267	Direct
	2,538,890	253,889	Indirect

Footnotes

These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. No additional value was paid by the Reporting Person in connection with the exchange.
Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value.
Includes RPI US LP Interests convertible into 172,210 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share.
Includes RPI US LP Interests convertible into 183,700 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share.